share_log

Does Jiangsu Yuyue Medical Equipment & Supply (SZSE:002223) Have A Healthy Balance Sheet?

Does Jiangsu Yuyue Medical Equipment & Supply (SZSE:002223) Have A Healthy Balance Sheet?

江苏裕越医疗设备及供应有限公司(SZSE:002223)的资产负债表健康吗?
Simply Wall St ·  06/10 02:46

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. As with many other companies Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SZSE:002223) makes use of debt. But the more important question is: how much risk is that debt creating?

David Iben说得好,“波动性并不是我们关心的风险。我们关心的是避免永久性的资本损失。”因此,明智的钱知道债务-通常涉及破产-是评估公司风险的一个非常重要的因素。就像许多其他公司一样,江苏裕越医疗器材供应股份有限公司(SZSE: 002223)利用债务。但更重要的问题是:那些债务带来了多少风险?

When Is Debt A Problem?

什么时候负债才是一个问题?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first step when considering a company's debt levels is to consider its cash and debt together.

当公司无法通过自由现金流或以有吸引力的价格提高资本来轻松履行这些义务时,债务和其他负债变得高风险。倘若情况恶劣,贷款人就能够控制公司。然而,一个更频繁但仍然代价高昂的情况是公司必须以折扣价发行股票,永久性地稀释股东,仅仅为了支撑其资产负债表。当然许多公司利用债务资助成长,没有任何负面影响。考虑一家公司的债务水平的第一步是将其现金和债务结合在一起。

What Is Jiangsu Yuyue Medical Equipment & Supply's Net Debt?

江苏裕越医疗器材供应的净债务是什么?

The image below, which you can click on for greater detail, shows that Jiangsu Yuyue Medical Equipment & Supply had debt of CN¥1.00b at the end of March 2024, a reduction from CN¥1.49b over a year. But it also has CN¥7.66b in cash to offset that, meaning it has CN¥6.65b net cash.

如下图所示(点击可放大),江苏裕越医疗器材供应在2024年3月底的债务为10亿元人民币,较去年的14.9亿元人民币减少。但它还有76.6亿元人民币的现金来弥补这个问题,这意味着它有66.5亿元人民币的净现金。

debt-equity-history-analysis
SZSE:002223 Debt to Equity History June 10th 2024
SZSE:002223股权与负债历史记录2024年6月10日

How Strong Is Jiangsu Yuyue Medical Equipment & Supply's Balance Sheet?

江苏裕越医疗器材供应的财务状况如何?

We can see from the most recent balance sheet that Jiangsu Yuyue Medical Equipment & Supply had liabilities of CN¥3.05b falling due within a year, and liabilities of CN¥965.2m due beyond that. Offsetting these obligations, it had cash of CN¥7.66b as well as receivables valued at CN¥1.07b due within 12 months. So it actually has CN¥4.71b more liquid assets than total liabilities.

我们可以从最新的财务状况表中看到,江苏裕越医疗器材供应有305亿元人民币的负债在一年内到期,而后面还有96520万元的负债。抵消这些义务,它有766亿元人民币的现金以及105亿元人民币的应收账款在12个月内到期。所以它实际上有471亿元人民币。总负债还多出了更多的流动资产。

This surplus suggests that Jiangsu Yuyue Medical Equipment & Supply has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Succinctly put, Jiangsu Yuyue Medical Equipment & Supply boasts net cash, so it's fair to say it does not have a heavy debt load!

这个盈余表明,江苏裕越医疗器材供应拥有稳健的资产负债表,很可能可以轻松消除其债务。简言之,江苏裕越医疗器材供应拥有净现金,因此没有沉重的债务负担!

Also good is that Jiangsu Yuyue Medical Equipment & Supply grew its EBIT at 11% over the last year, further increasing its ability to manage debt. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if Jiangsu Yuyue Medical Equipment & Supply can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

江苏裕越医疗器材供应去年EBIT增长11%,这也是好的,进一步增加了其管理债务的能力。毫无疑问,我们从资产负债表中了解到债务最多。但最终业务的未来盈利能力将决定江苏裕越医疗器材供应能否随着时间推移增强其资产负债表。因此,如果您关注未来,可以查看此免费报告,显示分析师的利润预测。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. Jiangsu Yuyue Medical Equipment & Supply may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Over the last three years, Jiangsu Yuyue Medical Equipment & Supply actually produced more free cash flow than EBIT. That sort of strong cash generation warms our hearts like a puppy in a bumblebee suit.

但是我们的最终考虑也很重要,因为公司不能用纸上利润付债务;它需要冰冷的现金。江苏裕越医疗器材供应在资产负债表上有净现金,但是看看它的收益前利息和税前利润(EBIt)与自由现金流的转换有多好,因为这将影响其管理债务的需求和能力。在过去的三年中,江苏裕越医疗器材供应实际上产生的自由现金流比EBIt还要多一些。这种强劲的现金生成方式让我们感到温馨,就像一个穿着大黄蜂衣服的小狗狗。

Summing Up

总之

While it is always sensible to investigate a company's debt, in this case Jiangsu Yuyue Medical Equipment & Supply has CN¥6.65b in net cash and a decent-looking balance sheet. The cherry on top was that in converted 108% of that EBIT to free cash flow, bringing in CN¥1.9b. So is Jiangsu Yuyue Medical Equipment & Supply's debt a risk? It doesn't seem so to us. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. We've identified 2 warning signs with Jiangsu Yuyue Medical Equipment & Supply , and understanding them should be part of your investment process.

虽然调查公司的债务总是明智的,但在这种情况下,江苏裕越医疗器材供应有665亿元人民币的净现金和一个看起来不错的财务状况。更棒的是它将108%的EBIt转换为自由现金流,带来19亿元人民币。那么江苏裕越医疗器材供应的债务是风险吗?我们不这么认为。在分析债务水平时,资产负债表是显而易见的起点。但是,最终,每个公司都可能存在超出资产负债表范围的风险。我们已经确定了江苏裕越医疗器材供应的2个警告信号,了解它们应该成为您的投资过程的一部分。

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

如果您有兴趣投资能够在不负债的情况下增长利润的企业,请查看这份免费列表,其中列出了在资产负债表上拥有净现金的成长型企业。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发